{
    "clinical_study": {
        "@rank": "38635", 
        "arm_group": [
            {
                "arm_group_label": "ivabradine", 
                "arm_group_type": "Active Comparator", 
                "description": "Exercise with ivabradine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Exercise with placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with CHF benefit from heart rate lowering, and the investigators have previously\n      demonstrated that this does not adversely affect exercise tolerance. In a pacemaker\n      population we also have shown that preventing heart rate lowering is detrimental in terms of\n      symptoms and prognosis.\n\n      The aim of the study is to therefore to establish whether heart rate limitation in patients\n      with heart failure has a negative impact on exercise capacity. If the investigators\n      establish that this is not the case, physicians will be able to confidently prescribe heart\n      rate lowering agents, and programme pacemakers to allow bradycardia without the concern that\n      there will be detrimental effects of symptom."
        }, 
        "brief_title": "Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure", 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to walk on a treadmill Able to provide consent Heart failure (or not) depending\n             upon the arm. Patients with atrial fibrillation to have had an AV node ablation (or\n             very slow response to AF)\n\n        Exclusion Criteria:\n\n          -  Cognitive impairment, known reaction to ivabradine, musculoskeletal issues limiting\n             walking on a treadmill."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086422", 
            "org_study_id": "CD13/10799"
        }, 
        "intervention": [
            {
                "arm_group_label": "ivabradine", 
                "intervention_name": "ivabradine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ivabradine", 
                    "Placebo"
                ], 
                "intervention_name": "Exercise", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "k.k.witte@leeds.ac.uk", 
                "last_name": "Klaus Witte, FRCP, MD", 
                "phone": "01133926642"
            }, 
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "zip": "LS2 9JT"
                }, 
                "name": "Leeds Teaching Hospitals NHS Trust"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "k.k.witte@leeds.ac.uk", 
            "last_name": "Klaus Witte, FRCP, MD", 
            "phone": "01133926642"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Each subject will undergo a full echocardiographic examination.We will assess LV systolic and diastolic function variables, mitral regurgitation, and pulmonary artery pressure.", 
            "measure": "Examining the effects of iatrogenic CI on exercise capacity", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086422"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "The Leeds Teaching Hospitals NHS Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Leeds Teaching Hospitals NHS Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}